AU2010234806B2 - Differentially expressed microRNAs as biomarkers for the diagnosis and treatment of Sjogren's syndrome - Google Patents

Differentially expressed microRNAs as biomarkers for the diagnosis and treatment of Sjogren's syndrome Download PDF

Info

Publication number
AU2010234806B2
AU2010234806B2 AU2010234806A AU2010234806A AU2010234806B2 AU 2010234806 B2 AU2010234806 B2 AU 2010234806B2 AU 2010234806 A AU2010234806 A AU 2010234806A AU 2010234806 A AU2010234806 A AU 2010234806A AU 2010234806 B2 AU2010234806 B2 AU 2010234806B2
Authority
AU
Australia
Prior art keywords
mir
level
increase
hsa
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010234806A
Other languages
English (en)
Other versions
AU2010234806A1 (en
Inventor
Ilias Alevizos
Gabor Illei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Health and Human Services filed Critical United States Department of Health and Human Services
Publication of AU2010234806A1 publication Critical patent/AU2010234806A1/en
Application granted granted Critical
Publication of AU2010234806B2 publication Critical patent/AU2010234806B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2010234806A 2009-03-31 2010-03-31 Differentially expressed microRNAs as biomarkers for the diagnosis and treatment of Sjogren's syndrome Ceased AU2010234806B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16514209P 2009-03-31 2009-03-31
US61/165,142 2009-03-31
PCT/US2010/029307 WO2010117829A2 (en) 2009-03-31 2010-03-31 Differentially expressed micrornas as biomarkers for the diagnosis and treatment of sjögren's syndrome

Publications (2)

Publication Number Publication Date
AU2010234806A1 AU2010234806A1 (en) 2011-09-08
AU2010234806B2 true AU2010234806B2 (en) 2014-05-22

Family

ID=42936826

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010234806A Ceased AU2010234806B2 (en) 2009-03-31 2010-03-31 Differentially expressed microRNAs as biomarkers for the diagnosis and treatment of Sjogren's syndrome

Country Status (6)

Country Link
US (1) US8785414B2 (enExample)
EP (1) EP2414549A4 (enExample)
JP (1) JP2012522508A (enExample)
AU (1) AU2010234806B2 (enExample)
CA (1) CA2754412A1 (enExample)
WO (1) WO2010117829A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6211511B2 (ja) * 2011-04-18 2017-10-11 ディアミール, エルエルシーDiamir, Llc ｍｉＲＮＡに基づくユニバーサルスクリーニングテスト（ＵＳＴ）
CA2839896A1 (en) * 2011-06-21 2012-12-27 Alnylam Pharmaceuticals, Inc. Assays and methods for determining activity of a therapeutic agent in a subject
US9970932B2 (en) 2013-03-15 2018-05-15 Arizona Board Of Regents On Behalf Of Arizona State University Non-covalent patterned chemical features and use thereof in MALDI-based quality control
US10006919B2 (en) 2013-03-15 2018-06-26 Arizona Board Of Regents On Behalf Of Arizona State University Peptide array quality control
CN105917005B (zh) 2013-11-18 2020-09-11 迪阿米尔有限责任公司 使用来自体液的miRNA检测和监控帕金森病(PD)的方法
RU2753883C2 (ru) * 2015-09-18 2021-08-24 Ванадис Дайэгностикс Набор зондов для анализа образцов днк и способы их использования
US10975436B2 (en) 2016-01-05 2021-04-13 Diamir, Llc Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders
EP3433381B1 (en) 2016-03-21 2024-07-24 Diamir, LLC Methods of using mirnas from bodily fluids for detection and differentiation of neurodegenerative diseases
US10781487B2 (en) 2017-07-24 2020-09-22 Diamir, Llc miRNA-based methods for detecting and monitoring aging
US11584956B2 (en) 2018-12-21 2023-02-21 Microsoft Technology Licensing, Llc Selectively controllable cleavable linkers
US12415171B2 (en) 2018-12-21 2025-09-16 Microsoft Technology Licensing, Llc Regulation of DNA synthesis by nucleotides linked to protecting groups
GB201901120D0 (en) * 2019-01-28 2019-03-20 Imperial Innovations Ltd Methods
US12226746B2 (en) * 2019-06-07 2025-02-18 Microsoft Technology Licensing, Llc Reversing bias in polymer synthesis electrode array
US11773422B2 (en) 2019-08-16 2023-10-03 Microsoft Technology Licensing, Llc Regulation of polymerase using cofactor oxidation states
US11795450B2 (en) 2019-09-06 2023-10-24 Microsoft Technology Licensing, Llc Array-based enzymatic oligonucleotide synthesis
US11896945B2 (en) 2019-10-09 2024-02-13 Microsoft Technology Licensing, Llc High surface area coatings for solid-phase synthesis
US20250075258A1 (en) * 2021-07-16 2025-03-06 Exosome Diagnostics, Inc. Methods of detecting sjogren's syndrome using salivary exosomes
WO2023172087A1 (ko) * 2022-03-11 2023-09-14 연세대학교 산학협력단 Klk5, klk7, cstb, ube2v2, tmsb10 또는 pi3을 유효성분으로 포함하는 쇼그렌 증후군 진단용 바이오마커 조성물
WO2024054572A1 (en) * 2022-09-07 2024-03-14 Exosome Diagnostics, Inc. Methods of detecting sjögren's syndrome using salivary exosomes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008147974A1 (en) * 2007-05-23 2008-12-04 University Of South Florida Micro-rnas modulating immunity and inflammation
US20080306006A1 (en) * 2006-01-05 2008-12-11 The Ohio State University MicroRna-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Solid Cancers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635563B2 (en) 2004-06-30 2009-12-22 Massachusetts Institute Of Technology High throughput methods relating to microRNA expression analysis
ES2534300T3 (es) 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
US20060185027A1 (en) 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
AU2007205234B2 (en) 2006-01-05 2012-07-12 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
CA3042781C (en) 2006-04-03 2021-10-19 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
WO2008147430A2 (en) * 2006-10-11 2008-12-04 Nucleonics, Inc. Microrna-formatted multitarget interfering rna vector constructs and methods of using the same
WO2009100342A2 (en) * 2008-02-08 2009-08-13 Medimmune, Llc Disease markers and uses thereof
EP2350320A4 (en) * 2008-11-12 2012-11-14 Caris Life Sciences Luxembourg Holdings METHOD AND SYSTEMS FOR USE OF EXOSOMES FOR THE DETERMINATION OF PHENOTYPES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080306006A1 (en) * 2006-01-05 2008-12-11 The Ohio State University MicroRna-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Solid Cancers
WO2008147974A1 (en) * 2007-05-23 2008-12-04 University Of South Florida Micro-rnas modulating immunity and inflammation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ACH, R. A., et al, 2008, BMC Biotechnology, Vol. 8:69 *
WORLEY, L. A., et al, 2008, Melanoma Research, Vol. 18, No. 3, pages 184-190 *
ZHANG, X. et al, November 2008, Journal of Molecular Diagnostics, Vol. 10, No. 6, pages 513-519 *

Also Published As

Publication number Publication date
CA2754412A1 (en) 2010-10-14
AU2010234806A1 (en) 2011-09-08
US20120029056A1 (en) 2012-02-02
WO2010117829A2 (en) 2010-10-14
WO2010117829A3 (en) 2011-03-31
WO2010117829A8 (en) 2011-10-20
EP2414549A2 (en) 2012-02-08
EP2414549A4 (en) 2013-08-28
US8785414B2 (en) 2014-07-22
JP2012522508A (ja) 2012-09-27

Similar Documents

Publication Publication Date Title
US8785414B2 (en) Differentially expressed microRNAs as biomarkers for the diagnosis and treatment of Sjögren's syndrome
US20220213551A1 (en) Mirnas as biomakers for distinguishing benign from malignant thyroid neoplasms
EP2183393B1 (en) Microrna signatures in human ovarian cancer
AU2012265177B2 (en) Methods and devices for prognosis of cancer relapse
US20090233297A1 (en) Microrna markers for recurrence of colorectal cancer
US20140171484A1 (en) Tissue-specific micrornas and compositions and uses thereof
AU2012265177A1 (en) Methods and devices for prognosis of cancer relapse
JP2010504102A5 (enExample)
WO2014169226A2 (en) Methods of diagnosing and treating chronic pain
WO2011154008A1 (en) Microrna classification of thyroid follicular neoplasia
EP3261718B1 (en) Methods of detecting, diagnosing, and treating atherosclerotic plaque rupture
US9683263B2 (en) Detection and treatment of irritable bowel syndrome
WO2020081641A1 (en) Plasma and cerebrospinal fluid mirna biomarkers in intracerebral and subarachnoid hemorrhage
US9150926B2 (en) Diagnosis and treatment of adrenocortical tumors using human microRNA-483
US20220145392A1 (en) Microrna regulatory network as biomarkers of seizure in patients with spontaneous intracerebral hemorrhage
Forder Evaluation of circulating miRNA signatures as a blood test for the early detection of nasopharyngeal carcinoma
Kruhøffer et al. Establishment of miRNA profile from human whole blood in combination with other genetic data

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired